Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Macular Edema

A Practical Approach

Editor(s): Coscas G. (Créteil, Paris) 
Cunha-Vaz J. (Coimbra) 
Loewenstein A. (Tel Aviv) 
Soubrane G. (Créteil, Paris) 
Cover

Chapter 8

Cystoid Macular Edema in Uveitis

de Smet M.D.a–c · Okada A.A.d

Author affiliations

aRetina and Inflammatory Diseases Unit, Center for Specialized Ophthalmology, Clinique de Montchoisi, Lausanne, Switzerland; bDepartment of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands; cDepartment of Ophthalmology, Ghent State University, Ghent, Belgium; dDepartment of Ophthalmology, Kyorin University, Tokyo, Japan

Related Articles for ""

Coscas G (ed): Macular Edema. Dev Ophthalmol. Basel, Karger, 2010, vol 47, pp 136–147

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Chapter 8

Published online: August 10, 2010
Cover Date: 2010

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9434-9 (Print)
eISBN: 978-3-8055-9435-6 (Online)

Abstract

Macular edema is a major cause of morbidity in uveitis patients. Inflammatory mediators act on the integrity of the blood ocular barrier and on the function of the RPE pump. Chronicity leads to irreversible changes and is reported to cause up to 30% of permanent visual loss in uveitis patients. Assessing the presence and severity of edema with appropriate investigational techniques (Spectral domain OCT, and angiography) help to determine its reversibility and define a therapeutic strategy wherein intraocular steroids play a key role while RPE pump stimulators and surgery are restricted to more severe disease or the presence of tractional syndromes.

© 2010 S. Karger AG, Basel


References

  1. Pournaras CJ Rungger-Brändle E Riva CE , et al: Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008;27:284-330
  2. Foster CS Fong LP Singh G: Cataract surgery and intraocular lens implantation in patients with uveitis. Ophthalmology 1989;96:281-288
  3. Rothova A Suttorp-van Schulten MSA Terffers WF Kijlstra A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336
  4. Rothova A: Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007;18:487-492
  5. Lardenoye CWTA van Kooij B Rothova A: Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113:1446-1449
  6. de Boer J Wulffraat N Rothova A: Visual loss in uveitis of childhood. Br J Ophthalmol 2003;87:879-884
  7. Smith JA Mackensen F Sen HN , et al: Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009;116:1544-1551
  8. Monnet D Levinson RD Holland GN , et al: Longitudinal cohort study of patients with birdshot chorioretinopathy. 3. Macular imaging at baseline. Am J Ophthalmol 2007;144:818-828
  9. Johnson MW: Etiology and treatment of macular edema. Am J Ophthalmol 2009;147:11-21
  10. Kiss CG Barisani-Asenbauer T Maca S , et al: Reading performance of patients with uveitis-associated cystoid macular edema. Am J Ophthalmol 2006;142:620-624.e1
  11. Hazel A Petre K Armstrong RA: Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci 2000;41:1309-1315
  12. Markomichelakis NN Halkiadais I Pantelia E , et al: Patterns of macular edema in patients with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2005;111:946-953
  13. Catier A Tadayoni R Paques M , et al: Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005;140:200-206
  14. Tran THC de Smet MD Bodaghi B , et al: Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol 2008;92:922-927
  15. Acharya NR Hong KC Lee SM: Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148:303-309
  16. Markomichelakis NN Theodossiadis PG Sfikakis PP: Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537-540
  17. van Kooij B Rothova A Rijkers GT de Groot-Mijnes JDF: Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006;142:192-194
  18. Probst K Fijnheer R Rothova A: Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004;137:850-857
  19. Curnow SJ Falciani F Durrani OM , et al: Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005;46:4251-4259
  20. Leal E Manivannan A Hosoya K , et al: Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-reinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007;48:5257-5265
  21. van Kooij B Fijnheer R Roest M Rothova A: Trace microalbuminuria in inflammatory cystoid macular edema. Am J Ophthalmol 2004;138:1010-1015
  22. Lin P Loh AR Margolis TP , et al: Cigarette smoking as a risk factor for uveitis. Ophthalmology 2010;117:585-590
  23. Thorne JE Daniel E Jabs DA , et al: Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol 2008;145:841-846
  24. Kramer CK de Azevedo MJ da Costa Rodrigues T , et al: Smoking habit is associated with diabetic macular edema in type I diabetes mellitus patients. J Diabetes Complications 2008;22:430
  25. Pruett R Brockhurst RJ Letts N: Fluorescein angiography of peripheral uveitis. Am J Ophthalmol 1974;77:448-453
  26. van Kooij B Probst K Fijnheer R , et al: Risk factors for cystoid macular oedema in patients with uveitis. Eye 2008;22:256-260
  27. Markomichelakis NN Halkiadais I Pantelia E Peponis V Patelis A Theodossiadis P Theodossiadis G: Patterns of macular edema in patients with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2005;111:946-953
  28. Forooghian F Yeh S Faia LJ Nussenblatt RB: Uveitis foveal atrophy. Arch Ophthalmol 2009;127:179-186
  29. Gürlü VP Alimgil ML Esgin H: Fluorescein angiographic findings in cases with intermediate uveitis in the inactive phase. Can J Ophthalmol 2007;42:107-109
  30. Tugal-Tutkun I Herbort CP Khairallah M: The Angiographic Scoring for Uveitis Working Group (ASUWOG) : Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol 2008; E-pub ahead of print
  31. Nussenblatt RB Kaufman SC Palestine AG , et al: Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology 1987;94:1134-1139
  32. Kiernan DF Hariprasad SM Chin EK , et al: Prospective comparison of cirrus and stratus optical coherence tomography for quantifying retinal thickness. Am J Ophthalmol 2009;147:267-275
  33. Roesel M Henschel A Heinz C , et al: Fundus autofluorescence and spectral domain optical coherence tomography in uveitis macular edema. Graefes Arch Clin Exp Ophthalmol 2009;247:1685-1689
  34. Vujosevic S Midena E Pilotto E , et al: Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006;47:3044-3051
  35. Jabs DA Rosenbaum JT: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001;131:679
  36. Mochizuki M de Smet MD: Use of immunosuppressive agents in ocular diseases. Prog Retin Eye Res 1994;13:479-506
  37. Rhen T Cidlowski JA: Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723
  38. Venkatesh P Abhas Z Garg S Vohra R: Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 2007;245:59-67
  39. Markomichelakis NN Theodossiadis PG Pantalia E , et al: Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-650
  40. Hale S Lightman S: Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006;33:231-237
  41. Kötter I Günaydin I Zierhut M Stübiger N: The use of interferon αin Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-325
  42. Kötter I Eckstein AK Stübiger N Zierhut M: Treatment of ocular symptoms of Behçet's disease with interferon α2a: a pilot study. Br J Ophthalmol 1998;82:488-494
  43. Tugal-Tutkun I Güney-Tefekli E Urgancioglu M: Results of interferon-α therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-1695
  44. Deuter CME Kötter I Günaydin I , et al: Interferon a-2A: a new treatment option for long lasting refractory cystoid macular edema in uveitis?. Retina 2006;26:786-791
  45. Bodaghi B Gendron G Wechsler B , et al: Efficacy of interferon αin the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-359
  46. Plskova J Greiner K Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61
  47. Cunningham MA Edelman JL Kaushal S: Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008;53:139-149
  48. Sallam A Comer RM Chang JH , et al: Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008;126:200-205
  49. Okada AA Wakabayashi T Morimura Y , et al: Trans-tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Brit J Ophthalmol 2003;87:1-4
  50. Schindler RH Chandler D Thresher R Machemer R: The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417
  51. Beer PM Bakri SJ Singh RJ , et al: Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686
  52. Kok H Lau C Maycock N , et al: Out-come of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916
  53. Yamamoto Y Komatsu T Koura Y , et al: Intraocular pressure elevation after intravitreal or posterior sub-tenon triamcinolone acetonide injection. Can J Ophthalmol 2008;43:42-47
  54. Maca SM Abela-Formanek C Kiss CG , et al: Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 2009;37:389-396
  55. Sallam A Sheth HG Habot-Wilner Z Lightman S: Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am J Ophthalmol 2009;148:207-213
  56. Inatani M Iwao K Kawaji T , et al: Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol 2008;145:676-681
  57. Scott IU Flynn HW, Jr: Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12
  58. Bhavsar AR Googe JM , Jr Stockdale CR , et al: Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583
  59. Bhavsar AR Ip MS Glassman AR: The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456
  60. Chen SDM Lochhead J McDonald B Patel CK: Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol 2004;88:843-844
  61. Byun YS Park Y-H: Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009;25:159-162
  62. Thomas ER Wang J Ege E , et al: Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 2006;142:860-861
  63. Nozik RA: Periocular injection of steroids. Trans Am Acad Ophthalmol Otolaryngol 1972;76:695-705
  64. Narayanan R Mungcal JK Kenney MC , et al: Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 2006;47:722-728
  65. Chung H Hwang JJ Koh JY , et al: Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest Ophthalmol Vis Sci 2007;48:5742-5749
  66. Spitzer MS Yoeruek E Kaczmarek RT , et al: Sodium hyaluronate gels as a drug-release system for corticosteroids: release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol 2008;86:842-848
  67. Driot JY Novack GD Rittenhouse KD , et al: Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-275
  68. Jaffe GJ Martin D Callanan D , et al: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027
  69. Pearson P Leavy B Comstock T: Fluocinolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial (E-abstract). Invest Ophthalmol Vis Sci 2006;47:5442
  70. Hsu J: Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007;18:235-239
  71. Galor A Margolis R Kaiser PK Lowder CY: Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant. Arch Ophthalmol 2007;125:836-838
  72. Ufret-Vincenty RL Singh RP Lowder CY Kaiser PK: Cytomegalovirus retinitis after fluocinolone acetonide (RetisertTM) implant. Am J Ophthalmol 2007;143:334-335
  73. Taban MM Lowder CYMDP Kaiser PKM: Outcome of fluocinolone acetonide implant RetisertTM reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28:1280-1288
  74. Whitcup SM Csaky KG Podgor MJ , et al: A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996;103:1054-1062
  75. Schilling H Heiligenhaus A Laube T , et al: Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005;25:182-188
  76. Guex-Crosier Y Othenin-Girard P Herbort CP: Traitement différencié de l'oedème maculaire cystoide inflammatoire postopératoire et secondaire aux uvéites. Klin Monbl Augenheilkd 1992;200:367-373
  77. Missotten T van Laar JAM van der Loos TL , et al: Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 2007;144:838-843
  78. Papadaki T Zacharopoulos I Iaccheri B , et al: Somatostatin for uveitic cystoid macular edema (CME) . Ocul Immunol Inflamm 2005;13:469-470
  79. Kuijpers RWAM Baarsma S van Hagen PM: Treatment of cystoid macular edema with octreotide. N Engl J Med 1998;338:624-626

Article / Publication Details

First-Page Preview
Abstract of Chapter 8

Published online: August 10, 2010
Cover Date: 2010

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9434-9 (Print)
eISBN: 978-3-8055-9435-6 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.